The ImmunoSep trial set out to test whether an individualized approach—based on identifying either macrophage activation–like syndrome (MALS) or sepsis-induced immunoparalysis (SIP)—could translate into improved organ function during the early phase of illness.
The trial enrolled adult patients diagnosed with sepsis according to Sepsis-3 criteria across centers in six countries. Eligible participants had pneumonia (community-acquired, hospital-acquired, or ventilator-associated) or bacteremia and showed laboratory evidence consistent with either MALS or SIP. Classification was based on a ferritin threshold of more than 4420 ng/mL for MALS, or ferritin at or below that level, along with fewer than 5000 HLA-DR receptors on CD45/CD14 monocytes for SIP.
Participants were randomized to receive standard care with targeted immunotherapy or standard care with a matching placebo. Patients categorized with MALS received intravenous anakinra, while those identified with SIP were treated with subcutaneous recombinant human interferon gamma. The placebo group received both intravenous and subcutaneous placebo injections. Treatment was administered for up to 15 days.
Of the 672 patients screened, 281 were randomized, and 276 were included in the primary analysis. The average age was 70 years, and the median baseline SOFA score was 9, reflecting substantial organ dysfunction.
Key Findings:
- By day 9, 35.1% of patients receiving precision immunotherapy showed an improvement of at least 1.4 points in SOFA score, compared with 17.9% in the placebo group.
- The absolute difference between the groups was 17.2%, indicating a statistically significant benefit in organ function with precision immunotherapy.
- Despite these improvements, 28-day mortality did not differ meaningfully between the treatment and placebo groups.
- Serious treatment-emergent adverse events were common across all patients, as expected in severe sepsis.
- Anemia occurred more often among patients treated with anakinra.
- Bleeding events were more frequently reported in those who received interferon gamma.
Researchers highlighted key limitations: the primary outcome was a surrogate marker rather than a direct patient-centered measure like mortality; ferritin and HLA-DR testing may be difficult to implement widely due to limited availability and longer assay times; immune subtypes may shift over time; and the results apply only to sepsis linked to pneumonia or bacteremia.
"Despite these challenges, the trial provides evidence that an individualized immunotherapy strategy can meaningfully improve early organ dysfunction in sepsis. Further large-scale studies will be essential to determine whether this precision approach can ultimately improve survival and broader clinical outcomes," the authors concluded.
Reference:
Giamarellos-Bourboulis EJ, Kotsaki A, Kotsamidi I, et al. Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial. JAMA. Published online December 08, 2025. doi:10.1001/jama.2025.24175
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.